Chronic Rejection of Cardiac Transplant Clinical Trial
Official title:
Phase IV: Effect of Everolimus and CNI Minimalization on Renal Function.
The different mechanisms of action of Everolimus and cyclosporine suppress immune function
in synergistic manner. Thus it is postulated that the use of Everolimus in combination with
cyclosporine permits a significant cyclosporine dose reduction without loss of
immunosuppressive activity in the clinical setting.
The aim of the present study is to evaluate the evolution of renal function after initiation
of Everolimus and minimalisation of CNI dose.
Everolimus is a new proliferation signal inhibitor with immunosuppressive and
antiproliferative activity.
The mechanism of action of Everolimus is distinct from that of calcineurin inhibitors.
Cardiac allograft vasculopathy is the major cause of late death in cardiac transplant
patients.
The different mechanisms of action of Everolimus and cyclosporine suppress immune function
in synergistic manner. Thus it is postulated that the use of Everolimus in combination with
cyclosporine permits a significant cyclosporine dose reduction without loss of
immunosuppressive activity in the clinical setting.
The aim of the present study is to evaluate the evolution of renal function after initiation
of Everolimus and minimalisation of CNI dose.
;
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03808324 -
Heart Failure After Heart Transplantation Due to Chronic Rejection
|
N/A |